To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Science, Technology, Communications119-hr1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.. Sponsored by Rep. Budzinski, Nikki [D-IL-13]. Introduced 2025-02-06. House bill. 119th Congress. Latest action: Referred to the House Committee on Energy and Commerce.
- Sponsor
- Rep. Budzinski, Nikki [D-IL-13] (D), IL
- Introduced
- 2025-02-06
- Committees
- Energy and Commerce Committee
- Subjects
- Drug safety, medical device, and laboratory regulation; Prescription drugs
- Latest Action
- Referred to the House Committee on Energy and Commerce.
No roll-call vote data available for this bill.
Similar Bills
- 117-hr1060 — American Broadband Act 69% match 117th Congress
- 116-hr7352 — BROADBAND Leadership Act 45% match 116th Congress
- 118-hr3295 — BROADBAND Leadership Act 39% match 118th Congress
- 115-s3157 — STREAMLINE Small Cell Deployment Act 38% match 115th Congress
- 117-hr1061 — American Broadband Act 35% match 117th Congress
Investigate this bill →
Beneficiary scoring, topic classification, and fiscal analysis